Anavex Starts Phase I Clinical Trial To Evaluate ANAVEX 2-73 Print E-mail
By Staff and Wire Reports   
Wednesday, 06 July 2011 19:22
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 6, 2011.

Anavex Life Sciences Corp. (OTC:AVXL) announced that it has started the 30 mg dose step in its ongoing Phase I clinical trial to evaluate the Company's lead drug candidate for Alzheimer's disease ANAVEX 2-73.

The primary objective of the Phase I clinical trial is to evaluate the safety and tolerability of ANAVEX 2-73 in humans for the first time. The secondary objective of the Phase I trial is to determine the pharmacokinetic profile of single oral ascending doses of ANAVEX 2-73.

This is the third of six potential dose steps and follows the successful completion of the 1 mg and 10 mg dosing rounds. There have been no adverse effects recorded after the administration of ANAVEX 2-73 at the doses studied to date. Trial participants are receiving single, ascending oral doses of ANAVEX 2-73 with one group potentially advancing to a maximum single oral dose of 240 mg.  ANAVEX 2-73 Phase I trial is rapidly and positively advancing.

Positive safety data at lower doses has so far enabled the Company to skip one higher dosing step and increase the amount being administered by ten times, from 1 mg to 10 mg, instead of from 1mg to 5mg. This recommendation was unanimously recommended by the Safety Review Committee for ANAVEX 2-73 following their evaluation of the available safety data from the first group of healthy human volunteers in the initial dose step.

Also Wednesday:

APC Group, Inc. (PINKSHEETS: APCU) announced today the Company received a pre-paid sale of 178 MedReels at a cost of $50,000 from Bates Electric of Arnold, MO. for Parkway High School in St. Louis for their science labs.

BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced that it has named veteran operations management executive Richard Whipp as Director of Operations, effective immediately.

BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced preliminary revenue of $623,000 for its second quarter ended June 30, 2011; an increase of 33% compared to revenue of $467,771 reported in the same period last year.

Celsion Corporation (NASDAQ: CLSN) today announced the closing of its previously announced sale of $6.6 million of the Company's securities in a registered direct offering.

Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced Laszlo Radvanyi, Ph.D., an Associate Professor in the Department of Melanoma Medical Oncology Research at the University of Texas MD Anderson Cancer Center in Houston, has joined its Scientific and Medical Advisory Board.

On June 30, 2011 Grupo Casa Saba, S.A.B. de C.V. (NYSE: SAB) ("Saba", "GCS" or the "Company"), one of the leading Mexican distributors and Latin American retailers of pharmaceutical products, beauty aids, personal care and consumer goods, general merchandise and publications filed its annual report on Form 20-F for the fiscal year ended December 31, 2010 with the U.S. Securities and Exchange Commission (the "SEC").

Oncolytics Biotech Inc. (TSX: ONC) (NASDAQ:ONCY) ("Oncolytics") today announced the appointment of George M. Gill, MD as Chief Medical Officer. He has been Senior Vice President of Clinical Safety and Regulatory Affairs and an officer of Oncolytics since 2002.

Corporate Profile's financial website announces Ray Dirks update on Pluristem Therapeutics, Inc. (NASDAQ: PSTI).

Radient Pharmaceuticals Corporation (OTCQX: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has appointed Dilek Mir as Director of Business Development and Investor Relations.

Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced the effectiveness of a one-for-four reverse stock split of its share capital.

Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce that its President, Frank Oakes and Executive VP, Corporate Development & Finance, Darrell Brookstein responded to an NSF invitation and presented Stellar's Phase IIB proposal ( for full implementation of commercial scale aquaculture systems for KLH (Keyhole Limpet Hemocyanin) production and development and deployment of a validated KLH-based immunogenicity assay to a committee of Program Directors of the National Science Foundation (NSF) at their Arlington, VA headquarters on June 30th.

Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(PINK SHEETS:VRSEF) (the "Company" or "Verisante") is pleased to announce that the results of a pilot study on lung cancer detection will be published in the prestigious Journal of Thoracic Oncology in July.

VisualMED Clinical Solutions Corp. (The "Company") (PINKSHEETS: VMCS) (FRANKFURT: VA6.F) announces today that it is expecting its revenues for the quarter ended June 30th, 2011 to rise to an amount between $890,000 and $965,000.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus